Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611hxl

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 20	EVENTLINE will be removed from STN
NEWS 28	Mar 24	PATDPAFULL now available on STN
NEWS 29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 30	Apr 11	Display formats in DGENE enhanced
NEWS 31	Apr 14	MEDLINE Reload
NEWS 32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 33	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS 34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 35	Apr 28	RDISCLOSURE now available on STN
NEWS 36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 39	May 16	CHEMREACT will be removed from STN

```
 NEWS 40  May 19  Simultaneous left and right truncation added to WSCA
 NEWS 41  May 19  RAPRA enhanced with new search field, simultaneous left and
                  right truncation
 NEWS 42  Jun 02  Simultaneous left and right truncation added to CBNB

 NEWS EXPRESS  April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:22:01 ON 02 JUN 2003

=> fil reg
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   0.21       0.21

FILE 'REGISTRY' ENTERED AT 14:22:13 ON 02 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    1 JUN 2003  HIGHEST RN 523977-56-2
DICTIONARY FILE UPDATES:   1 JUN 2003  HIGHEST RN 523977-56-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 09840503.str

L1      STRUCTURE UPLOADED
```

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 CN,Hy

G2 C,Cy

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful
FULL SEARCH INITIATED 14:22:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 302448 TO ITERATE

100.0% PROCESSED 302448 ITERATIONS 234 ANSWERS
SEARCH TIME: 00.00.06

L2 234 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.15	148.36

FILE 'CAPLUS' ENTERED AT 14:22:50 ON 02 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 2 Jun 2003 VOL 138 ISS 23
FILE LAST UPDATED: 1 Jun 2003 (20030601/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l2
L3          30 L2

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       1.25     149.61

FILE 'REGISTRY' ENTERED AT 14:24:49 ON 02 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     1 JUN 2003  HIGHEST RN 523977-56-2
DICTIONARY FILE UPDATES:    1 JUN 2003  HIGHEST RN 523977-56-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 09840503.str

L4      STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4              STR
```



Hy [1]

G1 CN,[@1]

G2 C,Cy

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 14:25:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  15057 TO ITERATE

  6.6% PROCESSED    1000 ITERATIONS                                1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       293800 TO   308480
PROJECTED ANSWERS:              69 TO      533

L5            1 SEA SSS SAM L1

=> s l4
SAMPLE SEARCH INITIATED 14:25:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  15057 TO ITERATE

  6.6% PROCESSED    1000 ITERATIONS                                1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       293800 TO   308480
PROJECTED ANSWERS:              69 TO      533

L6            1 SEA SSS SAM L4
```

```
=> d scan
```

L6 1 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 4(1H)-Quinolinone, 7-methoxy-2-(4-methylphenyl)-6-(5-oxazolyl)- (9CI)
MF C20 H16 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

```
=> s l4 ful sub=l2
FULL SUBSET SEARCH INITIATED 14:25:40 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -    234 TO ITERATE

100.0% PROCESSED     234 ITERATIONS                          200 ANSWERS
SEARCH TIME: 00.00.01

L7          200 SEA SUB=L2 SSS FUL L4

=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    35.70     185.31

FILE 'CAPLUS' ENTERED AT 14:25:48 ON 02 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 2 Jun 2003  VOL 138 ISS 23
FILE LAST UPDATED: 1 Jun 2003  (20030601/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l7
L8          11 L7

=> d abs ibib hitstr 1-
YOU HAVE REQUESTED DATA FROM 11 ANSWERS - CONTINUE? Y/(N):y
```

L8 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2003 ACS
GI



I



II



III

AB Quinolone derivs. I are described [wherein: X = O or S; R1 = aliph., cycloaliph., or cycloalkylalkyl; R2 = cyano or (un)substituted heteroarom.; R3 = H, alkyl, cyano, CO2H, CO2R6, or CONR7R8; R4 = Alk1-L1-Alk2-R9; R5 = H or alkyl; or NR4R5 = (un)substituted heterocycloaliph. ring optionally fused to (un)substituted monocyclic C 6-12 arom. group or (un)substituted monocyclic C1-9 heteroarom.; R6 = alkyl; R7, R8 = H, alkyl; Alk1 = bond or (un)substituted aliph. chain; L1 = bond, linker atom or group; Alk2 = bond or C1-3 alkylene chain; R9 = H, (un)substituted (hetero)cycloaliph. or (hetero)arom.; provided that R4 .noteq. H, and with 2 excluded compds.; including salts, solvates, hydrates, tautomers, isomers, or N-oxides]. The compds. are potent inhibitors of IMP dehydrogenase (IMPDH), and are of use as immunosuppressants, anti-cancer agents, anti-inflammatory agents, antipsoriatics, and anti-viral agents. Synthetic examples include 67 invention compds. (7 claimed) and 41 intermediates. For instance, condensation of the ketene dithioacetal 5-[bis(methylsulfanyl)methylene]-2,2-dimethyl-[1,3]dioxane-4,6-dione, first with 3-methoxy-4-(oxazol-5-yl)aniline in refluxing EtOH (83%), then with indoline using HgCl2 (82%), gave the vicinal diamine intermediate II. This compd. was thermally cyclized by refluxing in di-Ph ether, to give 57% III, a specifically claimed compd. When assayed against IMPDH-catalyzed, NAD-dependent oxidn. of IMP in vitro, or in a human PMBC (peripheral blood mononuclear cell) proliferation assay, I had IC50 values of 5 .mu.M or below (no addnl. data).

ACCESSION NUMBER: 2003:334904 CAPLUS
DOCUMENT NUMBER: 138:353840
TITLE: 2-Aminoquinolone derivatives for use as IMPDH inhibitors
INVENTOR(S): Haughan, Alan Findlay; Dyke, Hazel Joan; Buckley,

George Martin; Davies, Natasha; Hannah, Duncan Robert; Richard, Marianna Dilani; Sharpe, Andrew; Williams, Sophie Caroline
PATENT ASSIGNEE(S): Celltech R & D Limited, UK
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035066	A1	20030501	WO 2002-GB4754	20021022

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2001-25365 A 20011023
GB 2002-5372 A 20020307

IT **519052-60-9P**, 4-[7-Methoxy-6-(oxazol-5-yl)-4-oxo-1,4-dihydroquinolin-2-yl]piperazine-1-carboxylic acid tert-butyl ester **519052-67-6P**, 1-[7-Methoxy-6-(oxazol-5-yl)-4-oxo-1,4-dihydroquinolin-2-yl]piperidine-4-carboxylic acid methyl ester **519052-74-5P**, 7-Methoxy-6-(oxazol-5-yl)-2-(2-oxopyrrolidin-1-yl)-1H-quinolin-4-one **519053-04-4P**, 7-Methoxy-6-(oxazol-5-yl)-2-(piperazin-1-yl)-1H-quinolin-4-one dihydrochloride
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; prepn. of aminoquinolone derivs. as IMPDH inhibitors)

RN 519052-60-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 519052-67-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 519052-74-5 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(2-oxo-1-pyrrolidinyl)-(9CI) (CA INDEX NAME)



RN 519053-04-4 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

IT **519052-55-2P**, 7-Methoxy-2-(morpholin-4-yl)-6-(oxazol-5-yl)-1H-quinolin-4-one **519052-65-4P**, 2-(2,3-Dihydroindol-1-yl)-7-methoxy-6-(oxazol-5-yl)-1H-quinolin-4-one **519052-77-8P**, 7-Methoxy-2-(2-methylpyrrolidin-1-yl)-6-(oxazol-5-yl)-1H-quinolin-4-one **519052-78-9P**, 1-(7-Methoxy-6-(oxazol-5-yl)-4-oxo-1,4-dihydroquinolin-2-yl)piperidine-4-carboxylic acid amide **519052-79-0P**, 7-Methoxy-6-(oxazol-5-yl)-2-[4-(pyrrolidin-1-yl)piperidin-1-yl]-1H-quinolin-4-one **519052-81-4P**, 2-(3,4-Dihydro-1H-isoquinolin-2-yl)-7-methoxy-6-(oxazol-5-yl)-1H-quinolin-4-one **519052-87-0P**, 2-(1,3-Dihydroisoindol-2-yl)-7-methoxy-6-(oxazol-5-yl)-1H-quinolin-4-one **519052-91-6P**, 2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-7-methoxy-6-(oxazol-5-yl)-1H-quinolin-4-one **519052-92-7P**, 2-(5-Bromo-2,3-dihydroindol-1-yl)-7-methoxy-6-(oxazol-5-yl)-1H-quinolin-4-one **519053-00-0P**, 7-Methoxy-6-(oxazol-5-yl)-2-(4-phenylpiperidin-1-yl)-1H-quinolin-4-one

519053-02-2P, 7-Methoxy-2-(2-methyl-2,3-dihydroindol-1-yl)-6-(oxazol-5-yl)-1H-quinolin-4-one **519053-05-5P**, 2-(4-Acetylpiperazin-1-yl)-7-methoxy-6-(oxazol-5-yl)-1H-quinolin-4-one **519053-07-7P**, 3-[4-[7-Methoxy-6-(oxazol-5-yl)-4-oxo-1,4-dihydroquinolin-2-yl]piperazin-1-yl]propanoic acid methyl ester formate salt **519053-09-9P**, 2-[4-(2,2-Dimethylpropyl)piperazin-1-yl]-7-methoxy-6-(oxazol-5-yl)-1H-quinolin-4-one formate **519053-11-3P**, 7-Methoxy-6-(oxazol-5-yl)-2-[4-(pyridin-3-ylmethyl)piperazin-1-yl]-1H-quinolin-4-one formate **519053-12-4P**, 2-(Azetidin-1-yl)-7-methoxy-6-(oxazol-5-yl)-1H-quinolin-4-one **519053-13-5P**, 7-Methoxy-6-(oxazol-5-yl)-2-(piperidin-1-yl)-1H-quinolin-4-one **519053-14-6P**, 7-Methoxy-2-[(S)-2-(methoxymethyl)pyrrolidin-1-yl]-6-(oxazol-5-yl)-1H-quinolin-4-one **519053-16-8P**, 7'-Methoxy-6'-(oxazol-5-yl)-3,4-dihydro-2H,1'H-[1,2']-biquinolinyl-4'-one **519053-18-0P**, 7-Methoxy-6-(oxazol-5-yl)-2-(pyrrolidin-1-yl)-1H-quinolin-4-one **519053-20-4P**, 1-[7-Methoxy-6-(oxazol-5-yl)-4-oxo-1,4-dihydroquinolin-2-yl]piperidine-4-carboxylic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of aminoquinolone derivs. as IMPDH inhibitors)

RN 519052-55-2 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-(4-morpholinyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 519052-65-4 CAPLUS
CN 4(1H)-Quinolinone, 2-(2,3-dihydro-1H-indol-1-yl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 519052-77-8 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-(2-methyl-1-pyrrolidinyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 519052-78-9 CAPLUS
CN 4-Piperidinecarboxamide, 1-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 519052-79-0 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-[4-(1-pyrrolidinyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 519052-81-4 CAPLUS
CN 4(1H)-Quinolinone, 2-(3,4-dihydro-2(1H)-isoquinolinyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 519052-87-0 CAPLUS
CN 4(1H)-Quinolinone, 2-(1,3-dihydro-2H-isoindol-2-yl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 519052-91-6 CAPLUS
CN 4(1H)-Quinolinone, 2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 519052-92-7 CAPLUS
CN 4(1H)-Quinolinone, 2-(5-bromo-2,3-dihydro-1H-indol-1-yl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 519053-00-0 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(4-phenyl-1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 519053-02-2 CAPLUS
CN 4(1H)-Quinolinone, 2-(2,3-dihydro-2-methyl-1H-indol-1-yl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 519053-05-5 CAPLUS
CN Piperazine, 1-acetyl-4-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 519053-07-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 519053-06-6
CMF C21 H24 N4 O5



CM 2

CRN 64-18-6
CMF C H2 O2



RN 519053-09-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 519053-08-8
CMF C22 H28 N4 O3



CM 2

CRN 64-18-6
CMF C H2 O2



RN 519053-11-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 519053-10-2
CMF C23 H23 N5 O3



CM 2

CRN 64-18-6
CMF C H2 O2



RN 519053-12-4 CAPLUS
CN 4(1H)-Quinolinone, 2-(1-azetidinyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 519053-13-5 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 519053-14-6 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519053-16-8 CAPLUS
CN [1(2H),2'-Biquinolin]-4'(1'H)-one, 3,4-dihydro-7'-methoxy-6'-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 519053-18-0 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(1-pyrrolidinyl)- (9CI) (CA

INDEX NAME)



RN 519053-20-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2003 ACS
GI



I



II

applicant

AB Title compds. I [wherein X1 = CO, SO, or SO2; X2 = CR3 or N; X3 = NH, O, or S; X4 = CR4 or N; X5 = CR5 or N; X6 = CR6 or N] were prepd. were prepd. as inosine monophosphate dehydrogenase (IMPDH) enzyme inhibitors. For example, acetalization of 4-nitro-2-methoxytoluene with AcOH (51%), redn. to the aldehyde (91%), and cycloaddn. with (p-tolylsulfonyl)methyl isocyanate gave 5-(4-nitro-2-methoxyphenyl)oxazole (84%), which was reduced to the amine (95%). Alkylation with Et benzoylacetate and cyclization afforded the 6-(5-oxazolyl)-4(1H)-quinolinone II. Thus, I are useful as therapeutic agents for IMPDH-assocd. disorders, such as allograft rejection (no data).

ACCESSION NUMBER: 2001:798220 CAPLUS
DOCUMENT NUMBER: 135:344472
TITLE: Preparation of 6-(5-oxazolyl)-4(1H)-quinolinones as inhibitors of IMPDH enzyme
INVENTOR(S): Iwanowicz, Edwin J.; Watterson, Scott H.; Dhar, T. G. Murali; Pitts, William J.; Gu, Henry H.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 263 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081340	A2	20011101	WO 2001-US12900	20010419
WO 2001081340	A3	20020523		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1276739	A2	20030122	EP 2001-928708	20010419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002040022	A1	20020404	US 2001-840503	20010423

PRIORITY APPLN. INFO.: US 2000-199420P P 20000424
WO 2001-US12900 W 20010419

OTHER SOURCE(S): MARPAT 135:344472

IT **371252-10-7P**, 2-[2,3-Dihydro-3-(methylamino)-1H-inden-5-yl]-7-

methoxy-6-(5-oxazolyl)-4(1H)-quinolinone hydrochloride
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)
RN 371252-10-7 CAPLUS
CN 4(1H)-Quinolinone, 2-[2,3-dihydro-3-(methylamino)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

IT **371249-67-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 6-(5-oxazolyl)-4(1H)-quinolinones as inhibitors of IMPDH enzyme)
RN 371249-67-1 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-phenyl- (9CI) (CA INDEX NAME)



IT **371249-88-6P**, 2-[2,3-Dihydro-3-(dimethylamino)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)
RN 371249-88-6 CAPLUS
CN 4(1H)-Quinolinone, 2-[3-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



IT **371251-98-8P**, (R)-2-[3-(Dimethylamino)-2,3-dihydro-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-99-9P**, (S)-2-[3-(Dimethylamino)-2,3-dihydro-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)

RN 371251-98-8 CAPLUS

CN 4(1H)-Quinolinone, 2-[(3R)-3-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371251-99-9 CAPLUS

CN 4(1H)-Quinolinone, 2-[(3S)-3-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **371249-69-3P 371249-72-8P 371249-75-1P**
371249-77-3P 371249-80-8P, 3-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]benzoic acid methyl ester
371249-84-2P, 2-[3-(Hydroxymethyl)phenyl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371249-85-3P**, 2-[3-(1-Hydroxy-1-

methylethyl)phenyl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371249-86-4P**, 7-Methoxy-2-[3-(4-methyl-1-piperazinyl)phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone **371249-91-1P**, 7-Methoxy-2-[3-(4-methyl-1-piperazinyl)phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone trifluoroacetic acid salt **371249-93-3P**, 2-(2,3-Dihydro-3-methoxy-1H-inden-5-yl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371249-97-7P 371249-98-8P 371249-99-9P 371250-00-9P 371250-01-0P 371250-03-2P 371250-04-3P 371250-05-4P 371250-06-5P 371250-07-6P 371250-09-8P 371250-11-2P 371250-12-3P 371250-14-5P 371250-15-6P 371250-16-7P 371250-17-8P 371250-18-9P 371250-20-3P 371250-22-5P 371250-23-6P 371250-25-8P 371250-27-0P 371250-29-2P 371250-31-6P 371250-33-8P 371250-35-0P 371250-37-2P 371250-39-4P 371250-41-8P 371250-43-0P 371250-45-2P 371250-47-4P 371250-48-5P 371250-49-6P 371250-50-9P 371250-51-0P 371250-52-1P 371250-53-2P 371250-54-3P 371250-55-4P 371250-56-5P 371250-57-6P 371250-58-7P**, 7-Methoxy-2-[3-[(4-methoxyphenyl)methoxy]phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone **371250-59-8P**, 2-(3-Hydroxyphenyl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371250-60-1P**, 2-[3-[2-(Dimethylamino)ethoxy]phenyl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371250-61-2P**, 2-(2,3-Dihydro-2-methyl-1H-isoindol-5-yl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371250-62-3P 371250-63-4P 371250-64-5P 371250-65-6P 371250-66-7P 371250-67-8P 371250-68-9P 371250-69-0P 371250-70-3P 371250-71-4P 371250-72-5P 371250-73-6P 371250-74-7P 371250-75-8P 371250-76-9P 371250-77-0P 371250-78-1P 371250-79-2P 371250-80-5P 371250-81-6P 371250-82-7P 371250-83-8P 371250-84-9P 371250-85-0P 371250-86-1P 371250-87-2P 371250-88-3P 371250-89-4P 371250-90-7P 371250-91-8P 371250-92-9P 371250-93-0P 371250-94-1P 371250-95-2P 371250-96-3P 371250-97-4P 371250-98-5P 371250-99-6P 371251-00-2P 371251-01-3P 371251-02-4P 371251-03-5P 371251-04-6P 371251-05-7P 371251-06-8P 371251-12-6P**, 2-[2,3-Dihydro-3-(methylamino)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-13-7P**, 2-[2,3-Dihydro-3-(1-pyrrolidinyl)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-16-0P**, 2-[2,3-Dihydro-3-(4-morpholinyl)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-19-3P**, 2-[3-(1-Azetidinyl)-2,3-dihydro-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-21-7P**, 7-Methoxy-2-[(3-methylphenyl)methyl]-6-(5-oxazolyl)-4(1H)-quinolinone **371251-29-5P**, 7-Methoxy-2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone **371251-36-4P**, 3-Hydroxy-7-methoxy-6-(5-oxazolyl)-2-phenyl-4(1H)-quinolinone **371251-40-0P**, 3-Hydroxy-7-methoxy-2-(2-methylphenyl)-6-(5-oxazolyl)-4(1H)-quinolinone **371251-41-1P**, 3-Hydroxy-7-methoxy-2-(3-methylphenyl)-6-(5-oxazolyl)-4(1H)-quinolinone **371251-42-2P**, 3-Hydroxy-7-methoxy-2-(4-methylphenyl)-6-(5-oxazolyl)-4(1H)-quinolinone **371251-43-3P**, 2-(3,4-Dimethylphenyl)-3-hydroxy-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-44-4P**, 3-Hydroxy-7-methoxy-2-(4-methoxyphenyl)-6-(5-oxazolyl)-4(1H)-quinolinone **371251-45-5P**, 2-(4-Chloro-3-methylphenyl)-3-hydroxy-7-methoxy-6-(5-

oxazolyl)-4(1H)-quinolinone **371251-47-7P**, 2-(4-Chloro-3-methylphenyl)-3-hydroxy-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone trifluoroacetate **371251-48-8P**, 2-(2,3-Dihydro-3-methoxy-1H-inden-5-yl)-3-hydroxy-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-50-2P**, 3-Hydroxy-7-methoxy-2-[2-(methylsulfonyl)phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone **371251-51-3P**, 2-[1-(Dimethylamino)-2,3-dihydro-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-53-5P**, 2-(2,3-Dihydro-3-methoxy-2,2-dimethyl-1H-inden-5-yl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-55-7P**, 2-(2,3-Dihydro-3-methoxy-1,1-dimethyl-1H-inden-5-yl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-57-9P**, trans-2-[3-(Dimethylamino)-2,3-dihydro-2-methoxy-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-60-4P**, trans-2-[3-(Dimethylamino)-2,3-dihydro-2-hydroxy-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-61-5P**, trans-6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-ol methylcarbamate **371251-62-6P**, Ethylcarbamic acid trans-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl ester **371251-63-7P**, (1-Methylethyl)carbamic acid trans-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl ester **371251-64-8P**, (2-Chloroethyl)carbamic acid trans-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl ester **371251-65-9P**, Imidodicarbonic acid trans-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl methyl ester **371251-66-0P**, 7-Methoxy-2-[4-methyl-3-(phenylmethoxy)phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone **371251-68-2P**, 2-(3-Hydroxy-4-methylphenyl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-70-6P**, 7-Methoxy-2-[3-(2-methoxyethoxy)-4-methylphenyl]-6-(5-oxazolyl)-4(1H)-quinolinone **371251-72-8P**, 7-Methoxy-2-[4-methyl-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone **371251-73-9P 371251-74-0P 371251-75-1P 371251-76-2P 371251-77-3P 371251-78-4P 371251-79-5P 371251-80-8P 371251-81-9P 371251-82-0P**, 6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-N,N,N-trimethyl-1H-inden-1-aminium **371251-83-1P**, 2-[3-(Dimethylamino)-2,3-dihydro-1H-inden-5-yl]-3-hydroxy-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-86-4P**, 1,4-Dihydro-3-hydroxy-7-methoxy-2-(4-methylphenyl)-4-oxo-6-quinolinecarbonitrile **371251-88-6P**, 1,4-Dihydro-3-hydroxy-7-methoxy-2-(3-methylphenyl)-4-oxo-6-quinolinecarbonitrile **371251-92-2P**, 2-(2,3-Dihydro-3-hydroxy-1H-inden-5-yl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-94-4P**, 2-(3,4-Dimethoxyphenyl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-97-7P**, 2-[5-[(Dimethylamino)methyl]-3-thienyl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371252-06-1P 371252-09-4P**, N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methylacetamide **371252-11-8P**, N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-2-methoxy-N-methylacetamide **371252-12-9P**, N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl-1H-imidazol-1-acetamide **371252-13-0P**, N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl-4-morpholineacetamide **371252-14-1P**, N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl-2H-1,2,3-triazol-2-acetamide **371252-15-2P**, N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl-1H-1,2,3-triazol-1-acetamide

371252-16-3P 371252-17-4P, Dimethylcarbamic acid 6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl ester **371252-18-5P**, 2-[2,3-Dihydro-1-(1-pyrrolidinyl)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371252-19-6P**, 4-Acetyl-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-3,4-dihydro-2H-1,4-benzoxazine **371252-21-0P**, 7-Methoxy-2-[4-(4-morpholinylmethyl)phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone **371252-22-1P**, 6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-N,N,N-trimethyl-1H-inden-1-aminium iodide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)

RN 371249-69-3 CAPLUS
CN 4(1H)-Quinolinone, 2-(3-bromophenyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371249-72-8 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-[3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 371249-75-1 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-(4-methylphenyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371249-77-3 CAPLUS
CN Benzeneacetic acid, 3-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-

quinolinyl]- (9CI) (CA INDEX NAME)



RN 371249-80-8 CAPLUS
CN Benzoic acid, 3-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 371249-84-2 CAPLUS
CN 4(1H)-Quinolinone, 2-[3-(hydroxymethyl)phenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371249-85-3 CAPLUS
CN 4(1H)-Quinolinone, 2-[3-(1-hydroxy-1-methylethyl)phenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371249-86-4 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[3-(4-methyl-1-piperazinyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371249-91-1 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[3-(4-methyl-1-piperazinyl)phenyl]-6-(5-oxazolyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 371249-86-4
CMF C24 H24 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 371249-93-3 CAPLUS
CN 4(1H)-Quinolinone, 2-(2,3-dihydro-3-methoxy-1H-inden-5-yl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371249-97-7 CAPLUS

CN 4(1H)-Quinolinone, 2-(3-furanyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371249-98-8 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-(3-methylphenyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371249-99-9 CAPLUS
CN 4(1H)-Quinolinone, 2-(2-fluorophenyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-00-9 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-methyl-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-01-0 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-3-methyl-6-(5-oxazolyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 371250-03-2 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(2-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 371250-04-3 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 371250-05-4 CAPLUS
CN Acetamide, N-[3-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]phenyl]-2-hydroxy-N-methyl- (9CI) (CA INDEX NAME)



RN 371250-06-5 CAPLUS
CN Acetamide, 2-(acetyloxy)-N-[3-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 371250-07-6 CAPLUS
CN 4-Morpholineacetamide, N-[3-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 371250-09-8 CAPLUS
CN Benzoic acid, 4-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 371250-11-2 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-(4-methoxyphenyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-12-3 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 371250-14-5 CAPLUS
CN 2-Quinolinepropanamide, N,N-diethyl-1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 371250-15-6 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 371250-16-7 CAPLUS
CN 4(1H)-Quinolinone, 2-(4-hydroxyphenyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-17-8 CAPLUS
CN 4(1H)-Quinolinone, 2-(3,4-dimethylphenyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-18-9 CAPLUS
CN Benzenebutanoic acid, 4-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 371250-20-3 CAPLUS
CN Benzenebutanoic acid, 4-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 371250-22-5 CAPLUS
CN Benzeneacetic acid, 4-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 371250-23-6 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 371250-25-8 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 371250-27-0 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[3-(4-morpholinyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-29-2 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-(2-methylphenyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-31-6 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-[3-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 371250-33-8 CAPLUS
CN 4(1H)-Quinolinone, 2-[3-[(dimethylamino)methyl]phenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-35-0 CAPLUS
CN 4(1H)-Quinolinone, 3-bromo-2-[3-[(dimethylamino)methyl]phenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-37-2 CAPLUS
CN Benzenepropanoic acid, 3-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 371250-39-4 CAPLUS
CN 4(1H)-Quinolinone, 2-(2-hydroxyethyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-41-8 CAPLUS
CN 4(1H)-Quinolinone, 2-[(dimethylamino)methyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-43-0 CAPLUS
CN 4(1H)-Quinolinone, 2-(3-hydroxypropyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-45-2 CAPLUS
CN 4(1H)-Quinolinone, 2-(4-hydroxybutyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-47-4 CAPLUS
CN 4(1H)-Quinolinone, 2-(hydroxymethyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-48-5 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-(methoxymethyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-49-6 CAPLUS
CN 4(1H)-Quinolinone, 2-(2-hydroxypropyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-50-9 CAPLUS
CN Benzenesulfonamide, 4-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 371250-51-0 CAPLUS
CN 4(1H)-Quinolinone, 2-(hydroxyphenylmethyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-52-1 CAPLUS
CN 4(1H)-Quinolinone, 2-(1-hydroxyethyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-53-2 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 371250-54-3 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[3-[(3S)-3-methyl-1-piperazinyl]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371250-55-4 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[3-(4-morpholinylmethyl)phenyl]-6-(5-

oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-56-5 CAPLUS
CN 4(1H)-Quinolinone, 2-[4-(1-hydroxy-1-methylethyl)phenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-57-6 CAPLUS
CN 4(1H)-Quinolinone, 2-[4-(hydroxymethyl)phenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-58-7 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[3-[(4-methoxyphenyl)methoxy]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-59-8 CAPLUS

CN 4(1H)-Quinolinone, 2-(3-hydroxyphenyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-60-1 CAPLUS
CN 4(1H)-Quinolinone, 2-[3-[2-(dimethylamino)ethoxy]phenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-61-2 CAPLUS
CN 4(1H)-Quinolinone, 2-(2,3-dihydro-2-methyl-1H-isoindol-5-yl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-62-3 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(4-thiazolyl)- (9CI) (CA INDEX NAME)



RN 371250-63-4 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-[2-(1-piperidinyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



RN 371250-64-5 CAPLUS
CN 4(1H)-Quinolinone, 2-(3,5-dimethylphenyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-65-6 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[3-(methylthio)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-66-7 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[3-(methylsulfonyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-67-8 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[3-[4-(2-methoxyethyl)-1-piperazinyl]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-68-9 CAPLUS
CN 4(1H)-Quinolinone, 2-[3-(2,6-dimethyl-4-morpholinyl)phenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-69-0 CAPLUS
CN 4(1H)-Quinolinone, 2-(3-bromo-4-methylphenyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-70-3 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-[3-[[(tetrahydro-2-furanyl)methyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 371250-71-4 CAPLUS
CN 4(1H)-Quinolinone, 2-[3-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-72-5 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-(4-morpholinyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-73-6 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-(4-methyl-1-piperazinyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-74-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[5-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2-methylphenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 371250-75-8 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-(1-pyrrolidinyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-76-9 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[3-[(2-methoxyethyl)amino]-4-methylphenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-77-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[5-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2-methylphenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 371250-78-1 CAPLUS
CN 4(1H)-Quinolinone, 2-[3-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-4-methylphenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371250-79-2 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-(1-piperazinyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-80-5 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-(4-thiomorpholinyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-81-6 CAPLUS
CN 4(1H)-Quinolinone, 2-(3-bromo-4-methoxyphenyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-82-7 CAPLUS
CN 4(1H)-Quinolinone, 2-[3-(1,1-dioxido-4-thiomorpholinyl)-4-methylphenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-83-8 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methoxy-3-(4-morpholinyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-84-9 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methoxy-3-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371250-85-0 CAPLUS
CN 4(1H)-Quinolinone, 2-[3-(1-azetidinyl)-4-methoxyphenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-86-1 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-87-2 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methoxy-3-[[2-(methylamino)ethyl]amino]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-88-3 CAPLUS
CN 4(1H)-Quinolinone, 2-[3-[(2R)-2-(dimethylamino)-1-pyrrolidinyl]-4-methoxyphenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371250-89-4 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methoxy-3-[(2-methoxyethyl)amino]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-90-7 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methoxy-3-[[2-(4-morpholinyl)ethyl]amino]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-91-8 CAPLUS
CN Benzonitrile, 5-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 371250-92-9 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(5,6,7,8-tetrahydro-8-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 371250-93-0 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(5,6,7,8-tetrahydro-8-hydroxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 371250-94-1 CAPLUS
CN Carbamic acid, dimethyl-, 7-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1,2,3,4-tetrahydro-1-naphthalenyl ester (9CI) (CA INDEX NAME)



RN 371250-95-2 CAPLUS
CN 4(1H)-Quinolinone, 2-[8-(dimethylamino)-5,6,7,8-tetrahydro-2-naphthalenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-96-3 CAPLUS
CN 4(1H)-Quinolinone, 2-ethyl-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-97-4 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-[3-(trifluoromethyl)phenyl]-(9CI) (CA INDEX NAME)



RN 371250-98-5 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-[4-(trifluoromethyl)phenyl]-(9CI) (CA INDEX NAME)



RN 371250-99-6 CAPLUS
CN 4(1H)-Quinolinone, 2-[4-(dimethylamino)-3,4-dihydro-2H-1-benzopyran-6-yl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-00-2 CAPLUS
CN 4(1H)-Quinolinone, 2-cyclohexyl-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-01-3 CAPLUS
CN 4(1H)-Quinolinone, 2-[3,4-dihydro-4-(1-pyrrolidinyl)-2H-1-benzopyran-6-yl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-02-4 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(1-phenylcyclopropyl)- (9CI) (CA INDEX NAME)



RN 371251-03-5 CAPLUS
CN 4(1H)-Quinolinone, 2-(4-bromophenyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-04-6 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[4-(4-methyl-1-piperazinyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-05-7 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[4-(4-morpholinyl)phenyl]-6-(5-oxazolyl)-(9CI) (CA INDEX NAME)



RN 371251-06-8 CAPLUS
CN Carbamic acid, [6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 371251-12-6 CAPLUS
CN 4(1H)-Quinolinone, 2-[2,3-dihydro-3-(methylamino)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-13-7 CAPLUS
CN 4(1H)-Quinolinone, 2-[2,3-dihydro-3-(1-pyrrolidinyl)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-16-0 CAPLUS
CN 4(1H)-Quinolinone, 2-[2,3-dihydro-3-(4-morpholinyl)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-19-3 CAPLUS
CN 4(1H)-Quinolinone, 2-[3-(1-azetidinyl)-2,3-dihydro-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-21-7 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[(3-methylphenyl)methyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-29-5 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-36-4 CAPLUS
CN 4(1H)-Quinolinone, 3-hydroxy-7-methoxy-6-(5-oxazolyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 371251-40-0 CAPLUS
CN 4(1H)-Quinolinone, 3-hydroxy-7-methoxy-2-(2-methylphenyl)-6-(5-oxazolyl)-(9CI) (CA INDEX NAME)



RN 371251-41-1 CAPLUS
CN 4(1H)-Quinolinone, 3-hydroxy-7-methoxy-2-(3-methylphenyl)-6-(5-oxazolyl)-(9CI) (CA INDEX NAME)



RN 371251-42-2 CAPLUS
CN 4(1H)-Quinolinone, 3-hydroxy-7-methoxy-2-(4-methylphenyl)-6-(5-oxazolyl)-(9CI) (CA INDEX NAME)



RN 371251-43-3 CAPLUS
CN 4(1H)-Quinolinone, 2-(3,4-dimethylphenyl)-3-hydroxy-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-44-4 CAPLUS
CN 4(1H)-Quinolinone, 3-hydroxy-7-methoxy-2-(4-methoxyphenyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-45-5 CAPLUS
CN 4(1H)-Quinolinone, 2-(4-chloro-3-methylphenyl)-3-hydroxy-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-47-7 CAPLUS
CN 4(1H)-Quinolinone, 2-(4-chloro-3-methylphenyl)-3-hydroxy-7-methoxy-6-(5-

oxazolyl)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 371251-45-5
CMF C20 H15 Cl N2 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 371251-48-8 CAPLUS
CN 4(1H)-Quinolinone, 2-(2,3-dihydro-3-methoxy-1H-inden-5-yl)-3-hydroxy-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-50-2 CAPLUS
CN 4(1H)-Quinolinone, 3-hydroxy-7-methoxy-2-[2-(methylsulfonyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-51-3 CAPLUS
CN 4(1H)-Quinolinone, 2-[1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-53-5 CAPLUS
CN 4(1H)-Quinolinone, 2-(2,3-dihydro-3-methoxy-2,2-dimethyl-1H-inden-5-yl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-55-7 CAPLUS
CN 4(1H)-Quinolinone, 2-(2,3-dihydro-3-methoxy-1,1-dimethyl-1H-inden-5-yl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-57-9 CAPLUS
CN 4(1H)-Quinolinone, 2-[(2R,3R)-3-(dimethylamino)-2,3-dihydro-2-methoxy-1H-

inden-5-yl]-7-methoxy-6-(5-oxazolyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 371251-60-4 CAPLUS
CN 4(1H)-Quinolinone, 2-[(2R,3R)-3-(dimethylamino)-2,3-dihydro-2-hydroxy-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 371251-61-5 CAPLUS
CN 4(1H)-Quinolinone, 2-[(2R,3R)-3-(dimethylamino)-2,3-dihydro-2-[[(methylamino)carbonyl]oxy]-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 371251-62-6 CAPLUS
CN Carbamic acid, ethyl-, (1R,2R)-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 371251-63-7 CAPLUS
CN Carbamic acid, (1-methylethyl)-, (1R,2R)-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 371251-64-8 CAPLUS
CN Carbamic acid, (2-chloroethyl)-, (1R,2R)-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 371251-65-9 CAPLUS
CN Imidodicarbonic acid, (1R,2R)-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 371251-66-0 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-(phenylmethoxy)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-68-2 CAPLUS
CN 4(1H)-Quinolinone, 2-(3-hydroxy-4-methylphenyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-70-6 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[3-(2-methoxyethoxy)-4-methylphenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-72-8 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-73-9 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-[2-(4-morpholinyl)ethoxy]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-74-0 CAPLUS
CN 4(1H)-Quinolinone, 2-[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methylphenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-75-1 CAPLUS
CN 4(1H)-Quinolinone, 2-[3-[2-(dimethylamino)ethoxy]-4-methylphenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-76-2 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-[(tetrahydro-3-furanyl)methoxy]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-77-3 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-[(1-methyl-4-piperidinyl)oxy]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-78-4 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371251-79-5 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-80-8 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-[2-(2-pyridinyl)ethoxy]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-81-9 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-[(tetrahydro-2-furanyl)methoxy]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-82-0 CAPLUS
CN 1H-Inden-1-aminium, 6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-N,N,N-trimethyl- (9CI) (CA INDEX NAME)



RN 371251-83-1 CAPLUS
CN 4(1H)-Quinolinone, 2-[3-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-3-hydroxy-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-86-4 CAPLUS
CN 6-Quinolinecarbonitrile, 1,4-dihydro-3-hydroxy-7-methoxy-2-(4-methylphenyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 371251-88-6 CAPLUS
CN 6-Quinolinecarbonitrile, 1,4-dihydro-3-hydroxy-7-methoxy-2-(3-methylphenyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 371251-92-2 CAPLUS
CN 4(1H)-Quinolinone, 2-(2,3-dihydro-3-hydroxy-1H-inden-5-yl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-94-4 CAPLUS
CN 4(1H)-Quinolinone, 2-(3,4-dimethoxyphenyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-97-7 CAPLUS
CN 4(1H)-Quinolinone, 2-[5-[(dimethylamino)methyl]-3-thienyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371252-06-1 CAPLUS
CN Carbamic acid, [6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 371252-09-4 CAPLUS
CN Acetamide, N-[6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 371252-11-8 CAPLUS
CN Acetamide, N-[6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 371252-12-9 CAPLUS
CN 1H-Imidazole-1-acetamide, N-[6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 371252-13-0 CAPLUS
CN 4-Morpholineacetamide, N-[6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 371252-14-1 CAPLUS
CN 2H-1,2,3-Triazole-2-acetamide, N-[6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 371252-15-2 CAPLUS
CN 1H-1,2,3-Triazole-1-acetamide, N-[6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 371252-16-3 CAPLUS
CN Carbamic acid, [6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 371252-17-4 CAPLUS
CN Carbamic acid, dimethyl-, 6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl ester (9CI) (CA INDEX NAME)



RN 371252-18-5 CAPLUS
CN 4(1H)-Quinolinone, 2-[2,3-dihydro-1-(1-pyrrolidinyl)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371252-19-6 CAPLUS
CN 2H-1,4-Benzoxazine, 4-acetyl-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 371252-21-0 CAPLUS
CN 4(1H)-Quinolinone, 7-methoxy-2-[4-(4-morpholinylmethyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371252-22-1 CAPLUS
CN 1H-Inden-1-aminium, 6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-N,N,N-trimethyl-, iodide (9CI) (CA INDEX NAME)



● I⁻

L8 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2003 ACS
GI



I



II

AB Title compds. I [R1 = alkyl, cycloalkyl, Ph, alkoxy, halo, NO2, NH2, (un)substituted heterocyclyl, etc.; n = 1, 2, 3; R2 = alkyl, (un)substituted Ph, heterocyclyl, etc.; R3 = H, alkyl, Ph, alkoxy, CN, etc.; R2R3 = fused ring system; R4 = alkyl, alkenyl, benzyl, (un)substituted phenyl] were prepd. as antiviral agents. Thus, II (R4 = H) was prepd. in 81% yield by reaction of 4-isopropylaniline with Et 2-benzoylpropionate in EtOH contg. polyphosphoric acid at 160.degree., and subsequent ethylation by EtI in the presence of K2CO3 in DMF gave II (R4 = Et). I were tested against picornaviruses, rhinoviruses, and rotaviruses.

ACCESSION NUMBER: 2001:167663 CAPLUS
DOCUMENT NUMBER: 134:207726
TITLE: 1,2-Disubstituted 1,4-dihydro-4-oxoquinoline compounds and their antiviral activity
INVENTOR(S): Tamura, Takashi; Kuriyama, Haruo; Agoh, Masanobu; Agoh, Yumi; Soga, Manabu; Mori, Teruyo
PATENT ASSIGNEE(S): Maruishi Pharmaceutical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 64 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1081138	A1	20010307	EP 2000-118673	20000829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001064259	A2	20010313	JP 1999-242700	19990830
JP 2001064261	A2	20010313	JP 1999-242701	19990830
JP 3259089	B2	20020218		
JP 2001089455	A2	20010403	JP 1999-262883	19990917
JP 2001089476	A2	20010403	JP 1999-262884	19990917
US 6541470	B1	20030401	US 2000-649596	20000829

PRIORITY APPLN. INFO.:
JP 1999-242700 A 19990830
JP 1999-242701 A 19990830
JP 1999-262883 A 19990917
JP 1999-262884 A 19990917

OTHER SOURCE(S): MARPAT 134:207726

IT **328398-76-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(1,2-disubstituted 1,4-dihydro-4-oxoquinolines as antiviral agents)
RN 328398-76-1 CAPLUS
CN 4(1H)-Quinolinone, 1-methyl-2-phenyl-6-(3-pyridinyl)- (9CI) (CA INDEX

NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

To: Laurelee Duncan faxed on 6/3/03

L8 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2003 ACS
GI For diagram(s), see printed CA Issue.
AB Quinolinyl ketones I [A = II, III; X = NH, O, S; B = (substituted) arom.; R2 = H, halo, lower (halo)alkyl, (hetero atom-contg.) cycloalkyl, (substituted) aryl, etc.; R3 = H, halo, lower (halo)alkyl, (hetero atom-contg.) cycloalkyl, alkoxyalkyl, (substituted) aryl, etc.; R2 and R3 may form (N-, O-, or S-contg.) (substituted) ring.; R1 = CR4R5R6; R4, R5 = H, lower (halo)alkyl, (hetero atom-contg.) cycloalkyl, lower (halo)alkyloxy, etc.; R4 and R5 may form (N-, O-, or S-contg.) (substituted) ring.; R6 = H, lower (halo)alkyl, (hetero atom-contg.) cycloalkyl, (substituted) (hetero)aryl, etc.] and IV (A, B, X, R2, R3 = same as I) or their pharmaceutically acceptable salts, useful as inhibitors of interleukin-1 prodn., are prepd. 7-Ethyl-4-methoxymethoxy-3,5,8-trimethoxy-2-quinolinecarboxaldehyde (prepn. given) was condensed with MeCOCMe(OH)Me in MeOH in the presence of LiOH.H2O at 50-60.degree. for 1 h and deprotected with HCl in AcOEt at room temp. for 10 min to give 71% I (A = 1,4-dihydro-7-ethyl-4-oxo-3,5,8-trimethoxyquinolinyl, R1 = CMe2OH) (V). V in vitro showed IC50 of 1.08 and 0.92 .mu.M against IL-.alpha. and IL-.beta. resp.

ACCESSION NUMBER: 1997:765311 CAPLUS
DOCUMENT NUMBER: 128:88793
TITLE: Preparation of .alpha.,.beta.-unsaturated quinolinyl ketones as inhibitors of interleukin-1 production
INVENTOR(S): Tanaka, Masayuki; Okita, Makoto; Miyamoto, Mitsuaki; Kaneko, Toshihiko; Kawahara, Tetsuya; Akamatsu, Keiji; Chiba, Kenichi; Obaishi, Hiroshi; Sakurai, Hideki; Abe, Shinya; Kobayashi, Kiyokazu; Yamanaka, Teiji
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 116 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09309879	A2	19971202	JP 1996-148569	19960520

PRIORITY APPLN. INFO.: JP 1996-148569 19960520
OTHER SOURCE(S): MARPAT 128:88793
IT **185206-37-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of quinolinyl ketones as inhibitors of interleukin-1 prodn.)
RN 185206-37-5 CAPLUS
CN 6-Quinolinecarbonitrile, 1,4-dihydro-3-methyl-4-oxo-2-(3-oxo-1-butenyl)-(9CI) (CA INDEX NAME)



L8 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2003 ACS
GI



I



II



III

AB Trifluoroacetamido derivs. I (Q = O; R = Br, I; X = CN, CO2Et, NO2) react with phosphorane Ph3P:CHCO2Et in boiling toluene to give the corresponding enamines I (Q = CHCO2Et; same R, X), which are precursors of the trifluoromethylated indoles II and quinolones III.

ACCESSION NUMBER: 1997:520074 CAPLUS
DOCUMENT NUMBER: 127:205460
TITLE: Synthesis of indoles and quinolones by sequential Wittig and Heck reactions
AUTHOR(S): Latham, Elliot J.; Stanforth, Stephen P.
CORPORATE SOURCE: Department of Chemical and Life Sciences, University of Northumbria at Newcastle, Newcastle upon Tyne, NE1 8ST, UK
SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1997), (14), 2059-2063
CODEN: JCPRB4; ISSN: 0300-922X
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 127:205460
IT **183989-99-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of indoles and quinolones by sequential Wittig and Heck reactions)
RN 183989-99-3 CAPLUS
CN 3-Quinolinecarboxylic acid, 6-cyano-1,4-dihydro-4-oxo-2-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)


H
N
CF3
NC
C
OEt
O
O

L8 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2003 ACS
GI For diagram(s), see printed CA Issue.
AB .alpha.,.beta.-Unsatd. ketone derivs. represented by general formula RCH:CHCOR1 [R = Q, Q1; wherein Z = NH, O, S; ring B = an optionally substituted arom. ring; R2 = H, halo, optionally halogenated lower alkyl, etc.; R3 = H, optionally halogenated lower alkyl, cycloalkyl optionally having heteroatom(s), alkoxyalkyl, optionally substituted aryl, optionally substituted heteroaryl, etc.; R1 = CR4R5R6; wherein R4, R5 = H, optionally halogenated lower alkyl, etc.; R6 = H, optionally halogenated lower alkyl, cycloalkyl optionally having heteroatom(s), optionally substituted aryl, optionally substituted heteroaryl, etc.] or pharmacol. acceptable salts thereof, which are useful for the prevention and treatment of interleukin 1 prodn.-related diseases, e.g. inflammation, are prepd. Thus, 1.68 g 7-ethyl-4-methoxymethoxy-3,5,8-trimethoxy-2-quinolinecarboxaldehyde and 1.0 g 3-hydroxy-3-methyl-2-butanone were dissolved in MeOH, treated with 0.21 g LiOH.H2O and heated at 50-60.degree. for 1 h to give, after treatment of the product with 1 N aq. HCl in EtOAc, the title quinolinylbutenone deriv. (I; R7 = R10 = OMe, R8 = H, R9 = Et, R11 = CMe2OH). The latter compd. and I (R7 = R9 = R10 = H, R8 = Cl, R2 = R11 = Me) showed IC50 of 1.08 and <0.1 nM, resp., for inhibiting the prodn. of interleukin 1.alpha. in human peripheral monocyte and 0.92 and <0.1 nM, resp., for inhibiting the prodn. of interleukin 1.beta. in human peripheral monocyte.
ACCESSION NUMBER: 1997:41948 CAPLUS
DOCUMENT NUMBER: 126:59875
TITLE: Preparation of beta-heterocyclyl-alpha, beta-unsaturated ketone derivatives as inhibitors of interleukin 1 production
INVENTOR(S): Tanaka, Masayuki; Okita, Makoto; Miyamoto, Mitsuaki; Kaneko, Toshihiko; Kawahara, Tetsuya; Akamatsu, Keishi; Chiba, Kenichi; Obaishi, Hiroshi; Sakurai, Hideki; Abe, Shinya; Kobayashi, Seiichi; Yamanaka, Takashi
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan; Tanaka, Masayuki; Okita, Makoto; Miyamoto, Mitsuaki; Kaneko, Toshihiko; Kawahara, Tetsuya; Akamatsu, Keishi; Chiba, Kenichi; Obaishi, Hiroshi; et al.
SOURCE: PCT Int. Appl., 254 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9636608	A1	19961121	WO 1996-JP1330	19960520
W: CA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 08311032	A2	19961126	JP 1995-142394	19950518

PRIORITY APPLN. INFO.: JP 1995-142394 19950518
OTHER SOURCE(S): MARPAT 126:59875
IT **185204-09-5P 185206-37-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of .beta.-heterocyclyl-.alpha., .beta.-unsatd. ketone derivs. as inhibitors of interleukin 1 prodn.)
RN 185204-09-5 CAPLUS
CN 6-Quinolinecarbonitrile, 1,4-dihydro-2-(4-hydroxy-4-methyl-3-oxo-1-

pentenyl)-3-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 185206-37-5 CAPLUS
CN 6-Quinolinecarbonitrile, 1,4-dihydro-3-methyl-4-oxo-2-(3-oxo-1-butenyl)-
(9CI) (CA INDEX NAME)



L8 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2003 ACS
GI


I


II


III


IV

AB N-trifluoroacetylanilines I (R = Br, iodo, X = cyano, CO2Et, NO2) undergo a Wittig reaction with phosphorane Ph2P:CHCO2Et giving enamine derivs. II which are precursors to indoles III and quinolines IV.

ACCESSION NUMBER: 1996:633861 CAPLUS
DOCUMENT NUMBER: 126:18764
TITLE: Synthesis of indoles and quinolones by sequential Wittig and Heck reactions
AUTHOR(S): Latham, Elliot J.; Stanforth, Stephen P.
CORPORATE SOURCE: Dep. Chem., Life Science, Univ. Northumbria Newcastle, Newcastle upon Tyne, NE1 8ST, UK
SOURCE: Chemical Communications (Cambridge) (1996), (19), 2253-2254
CODEN: CHCOFS; ISSN: 1359-7345
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **183989-99-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of indoles and quinolines by Wittig-Heck reaction of (trifluoroacetyl)anilines)
RN 183989-99-3 CAPLUS
CN 3-Quinolinecarboxylic acid, 6-cyano-1,4-dihydro-4-oxo-2-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)



same as previous

L8 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2003 ACS
GI



I

AB A novel series of title compds. was prepd. When evaluated in an in vitro binding assay using a guinea pig adrenal membrane prepn., compds. in this series generally gave ED50 values in the range 0.01-1 .mu.M. Structure-activity studies showed the quinoline N atom and a short alkyl chain at the quinoline 2-position to be essential for receptor binding. At 1-10 mg/kg in AII-infused, normotensive rats, the title compd. I exhibited a dose-related inhibition of the pressor response with a good duration of action at the higher doses. In a renal hypertensive rat model, I showed a rapid and sustained lowering of blood pressure at a dose of 5 mg/kg.

ACCESSION NUMBER: 1992:612398 CAPLUS
DOCUMENT NUMBER: 117:212398
TITLE: New nonpeptide angiotensin II receptor antagonists. 2. Synthesis, biological properties, and structure-activity relationships of 2-alkyl-4-(biphenylylmethoxy)quinoline derivatives
AUTHOR(S): Bradbury, Robert H.; Allott, Christopher P.; Dennis, Michael; Fisher, Eric; Major, John S.; Masek, Brian B.; Oldham, Alec A.; Pearce, Robert J.; Rankine, Neil; et al.
CORPORATE SOURCE: Dep. Chem., ICI Pharm., Macclesfield/Cheshire, SK10 4TG, UK
SOURCE: Journal of Medicinal Chemistry (1992), 35(22), 4027-38
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **135016-07-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and enol alkylation of)
RN 135016-07-8 CAPLUS
CN 6-Quinolinecarbonitrile, 2-ethyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



Intermediate

L8 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2003 ACS
GI



I



II



III

AB Modifications to the bicyclic ring system of the potent thymidylate synthase (TS) inhibitor N-[4-[N-[(2-amino-3,4-dihydro-4-oxo-6-quinazolinyl)methyl]-N-prop-2-ynylamino]benzoyl]-L-glutamic acid (CB3717) have led to the synthesis of a series of quinoline antifolates, e.g., I (R1 = Me, CH2OH, CF3; R2 = H, MeO, Me, cyano, Cl; R3 = HC.tplbond.CCH2, H, Et; R4 = H, F), bearing a variety of substituents at the C2 and C4 positions. In general the synthetic route involved the coupling of the appropriate di-Et N-[4-(prop-2-ynylamino)benzoyl]-L-glutamate II with a disubstituted 6-(bromomethyl)quinoline III followed by deprotection using mild alkali. The compds. were tested as inhibitors of partially purified L1210 TS. As a measure of cytotoxicity, the compds. were tested for their inhibition of the growth of L1210 cells in culture. Good enzyme inhibition and cytotoxicity were found for compds. contg. chloro, amino, or Me substituents at the C2 position with chloro or bromo substituents at C4. The effect on enzyme inhibition of varying the N10 substituent of I (R1 = Me, R2 = Cl, R3 = HC.tplbond.CCH2, R4 = H) was similar to that obsd. in the quinazolinone-contg. antifolates, indicating that the quinoline compds. may be interacting with the enzyme in a similar way to the quinazolinones. Also, the introduction of a 2'-fluoro substituent into the benzoyl ring of several of the quinoline antifolates, e.g., I (R1 = Cl, R2 = Cl, R3 = HC.tplbond.CCH2, R4 = F), led to a increase in both TS inhibition and the inhibition of L1210 cell growth. These data demonstrate that the N3-H of the pyrimidine ring of the quinazolinone antifolates is not required for binding to TS if appropriate substituents are placed at the C2 and C4 positions of the bicyclic ring system.

ACCESSION NUMBER: 1992:469707 CAPLUS
DOCUMENT NUMBER: 117:69707
TITLE: Quinoline antifolate thymidylate synthase inhibitors: variation of the C2- and C4-substituents
AUTHOR(S): Warner, Peter; Barker, Andrew J.; Jackman, Ann L.; Burrows, Kenneth D.; Roberts, Neal; Bishop, Joel A. M.; O'Connor, Brigid M.; Hughes, Leslie R.
CORPORATE SOURCE: Dep. Chem., ICI Pharm., Macclesfield/Cheshire, SK10 4TG, UK
SOURCE: Journal of Medicinal Chemistry (1992), 35(15), 2761-8
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **123638-03-9**
RL: RCT (Reactant); RACT (Reactant or reagent)

(redn. of)
RN 123638-03-9 CAPLUS
CN 6-Quinolinecarbonitrile, 1,4-dihydro-2-methyl-4-oxo- (9CI) (CA INDEX NAME)



same

intermediate

L8 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2003 ACS
GI



I



II

AB Title compds. I (R1 = H, alkyl, cycloalkyl, Ph, substituted alkyl; R2 = H, alkyl, cycloalkyl, HO2C, NC, O2N, Ph, phenylalkyl; R3, R4 = H, alkyl, alkoxy, fluoroalkoxy, halo, HO, F3C, NC, O2N, H2O, etc. R3R4 = C1-4 alkylenedioxy attached to adjacent C; R, R5 = H, alkyl, alkoxy, halo, F3C, NC, O2N; X = substituted C6H4, bond; Z = 1-tetrazol-5-yl, etc.) or salts thereof, useful for treatment of hypertension and congestive heart failure, are prepd. 2-Methyl-4-(2-(2-triphenylmethyl-2H-tetrazol-5-yl)biphenyl-4-yl)methoxy]quinoline (prepn. from 2-methyl-4-quinolone and the corresponding bromomethylbiphenyl given), dioxane.HCl and H2O were kept for 72 h to give title compd. II.HCl (III). In tests for antagonizing angiotensin II in vitro and in vivo, III showed IC50 1.7 .times. 1--8M, pA2 8.95, and ED50 of 0.5 mg/kg, i.v. In addn. I demonstrated a significant redn. in blood pressure at 50 mg/kg or less, without any overt toxicol. or other unsatd. pharmacol. effects. A large no. of I and intermediates were prepd. Pharmaceutical formulations comprising I are given.

ACCESSION NUMBER: 1991:471607 CAPLUS
DOCUMENT NUMBER: 115:71607
TITLE: Preparation of arylmethoxyquinolines (tetrazolylbiphenylylmethoxyquinolines) as cardiovascular agents.
INVENTOR(S): Roberts, David Anthony; Russell, Simon Thomas; Pearce, Robert James
PATENT ASSIGNEE(S): Imperial Chemical Industries PLC, UK
SOURCE: Eur. Pat. Appl., 33 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 412848	A2	19910213	EP 1990-308855	19900810

EP 412848	A3	19910410			
EP 412848	B1	19950118			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE					
CA 2023229	AA	19910212	CA 1990-2023229		19900802
NO 9003525	A	19910212	NO 1990-3525		19900810
GB 2234748	A1	19910213	GB 1990-17616		19900810
GB 2234748	B2	19930630			
AU 9060955	A1	19910214	AU 1990-60955		19900810
AU 623546	B2	19920514			
ZA 9006358	A	19910424	ZA 1990-6358		19900810
HU 54991	A2	19910429	HU 1990-4961		19900810
DD 298922	A5	19920319	DD 1990-343371		19900810
CN 1050187	A	19910327	CN 1990-106923		19900811
JP 03169863	A2	19910723	JP 1990-214223		19900813
JP 3010056	B2	20000214			
US 5444071	A	19950822	US 1993-58825		19930504
PRIORITY APPLN. INFO.:			GB 1989-18402	A	19890811
			GB 1990-3187	A	19900213
			US 1990-565764	B1	19900810

OTHER SOURCE(S): MARPAT 115:71607

IT **123638-03-9P 135016-07-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, in prepn. of cardiovascular agent)

RN 123638-03-9 CAPLUS
CN 6-Quinolinecarbonitrile, 1,4-dihydro-2-methyl-4-oxo- (9CI) (CA INDEX NAME)



intermediate

RN 135016-07-8 CAPLUS
CN 6-Quinolinecarbonitrile, 2-ethyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



IT **135016-07-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in prepn. of arylmethoxyquinoline cardiovascular agent)

RN 135016-07-8 CAPLUS
CN 6-Quinolinecarbonitrile, 2-ethyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in prepn. of cardiovascular agent

L8 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2003 ACS
GI For diagram(s), see printed CA Issue.
AB Title compds. I [R1, R2 = H, halo, OH, cyano, carbamoyl, NO2, NH2, alkyl, etc.; both R1, R2 .noteq. H; R3 = H, (substituted) alkyl; R4 = H, alkyl, alkenyl, alkynyl; Z = C6H4, naphthalene, heterocyclylene; the above groups may be substituted; R5NH = amino acid residue; X = halo, OH, cyano, alkyl, etc.; n = 0-2], useful as antitumor agents (no data), are prepd. from II (Y = leaving group, NR4ZCO2H). A mixt. of II (R1 = Me; R2 = Cl; R3 = Xn = H; Y = Br) (prepn. given), di-Et N-[2-fluoro-4-(prop-2-ynyl)aminobenzoyl]-L-glutamate, 2,6-lutidine, and DMF was heated at 70.degree., followed by sapon. of the resultant ester and acidification to give N-[4-[N-(4-chloro-2-methylquinolin-6-ylmethyl)-N-(prop-2-ynyl)amino]-2-fluorobenzoyl]-L-glutamic acid.

ACCESSION NUMBER: 1989:614940 CAPLUS
DOCUMENT NUMBER: 111:214940
TITLE: N-(quinolinylmethylaminoarylcarbonyl)amino acids as antitumor agents
INVENTOR(S): Burrows, Kenneth David; Hughes, Leslie Richard; Warner, Peter
PATENT ASSIGNEE(S): Imperial Chemical Industries PLC, UK; National Research and Development Corp.
SOURCE: Eur. Pat. Appl., 34 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 318225	A2	19890531	EP 1988-310972	19881121
EP 318225	A3	19901205		
EP 318225	B1	19940316		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 01258664	A2	19891016	JP 1988-296396	19881125
US 5112837	A	19920512	US 1990-584489	19900917

PRIORITY APPLN. INFO.: GB 1987-27737 19871126
US 1988-271271 19881115
OTHER SOURCE(S): MARPAT 111:214940
IT **123638-03-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in prepn. of antitumor agents)
RN 123638-03-9 CAPLUS
CN 6-Quinolinecarbonitrile, 1,4-dihydro-2-methyl-4-oxo- (9CI) (CA INDEX NAME)



Intermediates

```
=> d his

     (FILE 'HOME' ENTERED AT 14:22:01 ON 02 JUN 2003)

     FILE 'REGISTRY' ENTERED AT 14:22:13 ON 02 JUN 2003
L1             STRUCTURE UPLOADED
L2          234 S L1 FUL

     FILE 'CAPLUS' ENTERED AT 14:22:50 ON 02 JUN 2003
L3           30 S L2

     FILE 'REGISTRY' ENTERED AT 14:24:49 ON 02 JUN 2003
L4             STRUCTURE UPLOADED
L5            1 S L1
L6            1 S L4
L7          200 S L4 FUL  SUB=L2

     FILE 'CAPLUS' ENTERED AT 14:25:48 ON 02 JUN 2003
L8           11 S L7

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               50.31     235.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                               -7.16      -7.16

STN INTERNATIONAL LOGOFF AT 14:26:20 ON 02 JUN 2003
```

C:\Program Files\Stnexp\Queries\09840503.str

structure search after amendment.





chain nodes :
11 14 16
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
3-16 7-11 9-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
3-16 5-7 6-10 7-8 7-11 8-9 9-10 9-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:CN,Hy

G2:C,Cy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
14:CLASS 16:CLASS

C:\Program Files\Stnexp\Queries\09840503.str



chain nodes :
    11 14 16 17
ring nodes :
    1 2 3 4 5 6 7 8 9 10
chain bonds :
    3-16 7-11 9-14
ring bonds :
    1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
    3-16 5-7 6-10 7-8 7-11 8-9 9-10 9-14
normalized bonds :
    1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
    containing 1 :

G1:CN,[*1]

G2:C,Cy

Match level :
    1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
    14:CLASS 16:CLASS 17:Atom
Generic attributes :
    17:
    Saturation   : Unsaturated
    Type of Ring System   : Monocyclic